Navigation Links
AL-3000 A-Scan Unit

ProductsAL-3000 A-Scan Unit
Company Tomey Corp.
Item AL-3000 A-Scan Unit
Features 
  • IOL power is calculated automatically after entering the corneal curvature data & the desired postoperative refraction.
  • Immersion Cap is easy-to-use & disinfect.
  • High resolution color touch screen display provides a simple user interface.
  • PC memory card that stores data for up to 237 patients.
  • Using the optional pachymeter probe, the AL-3000 measures corneal thickness from 150 to 1,500m.
Description With touch screen control, automatic tone-assisted measurement & visual graphic displays, acquisition and evaluation of axial length measurements are almost effortless. Measuring modes include Normal, Dense Cataract, Aphakic & Pseudophakic of Silicone, Acrylic, PMMA & other IOLs. The AL-3000 can be used in either contact or immersion mode & measurements can be taken automatically or manually.
Info Tomey Corp.Call Tomey Corp. to buy products (US and Canada only; other locations use number below) USACanada1-866-405-0397

Customer Service: 888-449-4045
Web site: http://www.tomey.com/

Related medicine products :

1. Sonomed-315 Ultrasound Brain A-Scanner
2. Accutome A-Scan Plus
3. DGH-5100e Combination A-Scan/Pachymeter
4. DGH-5000e A-Scan unit
5. A-Scan Biometric Analyzer Model P20
6. Eye-Scan™ A-Scan
7. 100A+ Microscan A-Scan
8. AL-100 A-Scan Unit
9. A-Scan 100 - Ophthalmic Ultrasound
10. Burton A-Scan/Pachymeter Combo
11. Burton SS760A A-Scan
TAG: Scan Unit
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products:
(Date:12/3/2009)...discharged from hospitals on ventilator support an...ths later. Researchers from the Frances Payne Bol...ersity report these findings in American Journal ... only important outcome for patients," says Barbar...utes of Health-funded study, "Composite Outcomes o...
(Date:12/3/2009)...nd other healthcare professionals specialising in ...rt advice to guide them through the complex clinic...demic. , The paper, published online by the Am...m to stay alert to the significant concerns that s...ibly even bird flu (H5N1), to develop into a strai...
(Date:12/3/2009)...ected volunteers from virus linked to cervical can...s) -- The human papillomavirus (HPV) vaccine Cerva...six years, new research has found. , The vaccin...HPV-18) most commonly associated with cervical can...ed 15 to 25, with a normal cervical profile and no...
(Date:12/3/2009)...sive users also feel depressed or anxious when not...News) -- A survey of Chinese adolescents found tha... as likely to harm themselves as other teens. ,...ere living in the Chinese city of Guangzhou in Gua...ey had harmed themselves in some way within the pr...
(Date:12/3/2009)... The Arthritis Foundation bestowed it...ecipients during its national meeting in Atlanta. ...9 -- The Arthritis Foundation bestowed its highest... during its national meeting on Nov. 20 in Atlanta...rding Award for Distinguished Service ,The Arthrit...
Breaking Medicine News(10 mins):Health News:CWRU researchers report poor outcomes for CCI patients leaving hospitals on ventilators 2Health News:Transplant infectious disease experts provide pandemic guidance 2Health News:Transplant infectious disease experts provide pandemic guidance 3Health News:Cervarix Proves Effective Against HPV for Over 6 Years 2Health News:Teen Internet Addicts More Likely to Self-Harm: Study 2Health News:Arthritis Foundation Bestows Highest National Awards 2Health News:Arthritis Foundation Bestows Highest National Awards 3Health News:Arthritis Foundation Bestows Highest National Awards 4
... Increases Serum Sodium Levels Through Increase in...J., May 21 Otsuka Pharmaceutical Co., Ltd. (OPC) ...alization, Inc. (OPDC) announced today that the U....nts with clinically significant hypervolemic and e...
...la Join effort to Link Services, Caseworkers , , ...n,s Policy, Practice and Research at the Universi...th Montgomery County, Pa., Stewards of Change, Mic...eaking interoperable, real-time technology system ...
...g and Financing Offerings Help Healthcare Provider...bursement Deadlines , , PLANO, Texas, May 21 Pe...tsystems.com ) today announced the availability o...cause of the American Recovery and Reinvestment Ac...
...., May 21: Managed Health Care Associates, Inc. (M... is pleased to announce that Kimberly Binaso-Stwal...American Society of Health-System Pharmacists (ASH...esignated Fellows of ASHP, will be honored during ...
...By combining the expertise of its management liabi...as developed enhanced management liability coverag...hcare organizations, including hospitals, long ter...icy and protects healthcare organizations against ...
...This year 28 students in 17 states have won awards... by the Centers for Disease Control and Prevention... the contest invites fifth- and sixth-grade studen... of the winning posters are at www.fightthebitec...
Other Medicine News:Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 2Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 3Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 4Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 5Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 6Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 7Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 8Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 9Health News:University of Pennsylvania, Montgomery County Partner on Integrated, Interoperable System Design for Child Welfare 2Health News:Perot Systems Announces Special Financing Options for Stimulus Plan Healthcare Technology Upgrades 2Health News:Perot Systems Announces Special Financing Options for Stimulus Plan Healthcare Technology Upgrades 3Health News:MHA Clinical Director Kimberly Binaso, Pharm.D. Awarded 2009 ASHP Fellow 2Health News:MHA Clinical Director Kimberly Binaso, Pharm.D. Awarded 2009 ASHP Fellow 3Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 3Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 2Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 3
(Date:12/2/2009)...W YORK, Dec. 2 Reportlinker.com an...able in its catalogue: ,, Cardiac Pacemakers ...rtlinker.com/p0164335/Cardiac-Pacemakers---A-World...stitute a major segment in a rapidly expanding car...pacemakers market is characterized by relatively m...
(Date:12/2/2009)...ZER, Pa., Dec. 2 Cephalo...as filed a lawsuit in U.S. District Court in Delaw...ringement of U.S. Patent Nos. 7,132,570 (the ",570...516 (the ",516 Patent") for the Cephalon product N...on has a three-year period of marketing exclusivit...
(Date:12/2/2009)...W YORK, Dec. 2 Reportlinker.com an...able in its catalogue: ,, Multiple Myeloma Th..., http://www.reportlinker.com/p0164271/Multiple-...html ,, Given the severity, and relentless rel...t therapies and treatments to battle the disease a...
Breaking Medicine Technology:Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 2Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 3Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 4Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 5Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 6Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 7Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 8Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 9Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 10Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 3Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 4Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis 2Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis 3Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis 4Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis 5Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis 6AMT Starts Development LPLChip 28TM 29 With Progenika 5812 1AMT Starts Development LPLChip 28TM 29 With Progenika 5812 2AMT Starts Development LPLChip 28TM 29 With Progenika 5812 3Presentations of Cempra Pharmaceuticals CEM 102 28fusidic acid 29 at the Infectious Diseases Society of America Annual Meeting Highlight Properties T 5811 1Presentations of Cempra Pharmaceuticals CEM 102 28fusidic acid 29 at the Infectious Diseases Society of America Annual Meeting Highlight Properties T 5811 2Presentations of Cempra Pharmaceuticals CEM 102 28fusidic acid 29 at the Infectious Diseases Society of America Annual Meeting Highlight Properties T 5811 3Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo 28R 29 New Drug Application 5809 1Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo 28R 29 New Drug Application 5809 2Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo 28R 29 New Drug Application 5809 3Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo 28R 29 New Drug Application 5809 4Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo 28R 29 New Drug Application 5809 5